This is a case of a 70-year-old male who actually went to the emergency department with complaints of abdominal pain. In the work-up he underwent a CT computed tomography scan for this, and the CT scan was notable for a right renal mass with associated lymphadenopathy. There was a concern for a lytic lesion in his spine. He subsequently underwent a CT of the chest, which showed enumerable sub-centimeter pulmonary nodules with associated hilar lymphadenopathy. He was referred to urology where they elected to undergo a biopsy of the abdominal lymphadenopathy, which revealed clear cell renal cell carcinoma without any features. His past medical history was notable for ulcerative colitis as well as hypertension. And laboratory tests were notable for essentially normal chemistry with a CBC [complete blood count] showing a mild anemia at 12.5 g/dL with no thrombocytosis or neutrophilia.
This is obviously a common situation. Patient presents with new diagnosis of renal cell carcinoma. And we always have to ask what’s the best way to treat these patients. And I think with the advent of the data regarding targeted therapy combination with immunotherapy in the modern era, really looking at risk stratification is going to be important. And so the one I often use is the IMDC [International Metastatic Renal Cell Carcinoma Database Consortium] risk stratification, which takes into account clinical factors of the patient that were developed in the era of TKIs [tyrosine kinase inhibitors] but really are showing to have an important role in the era of immunotherapy. This is going to involve looking at the patient, the performance status, as well as lab values, and looking at the CBC, looking for neutrophilia, thrombocytosis, anemia, looking for elevated calcium, and really trying to get a sense for that patient and obviously whether they need therapy or not.
So in this patient who’s presenting with metastatic disease, if you’re going to pursue therapy, I would say he has intermediate-risk disease by the IMDC criteria.
Transcript edited for clarity.
Case: A 70-Year-Old Man with Intermediate-Risk RCC
A 70-year-old Caucasian man presented to ER complaining of blood in his urine and abdominal pain.
H & P
Labs
Imaging
Treatment
Follow-up
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC
March 6th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC
February 28th 2024New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.
Read More
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
February 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Read More